DexCom(US:DXCM) Prnewswire·2025-09-28 14:00Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices by DexCom, Inc. following allegations from a short report that highlighted serious issues with the company's G7 continuous glucose monitoring system [1][2]. Group 1: Investigation Details - Pomerantz LLP is representing investors of DexCom, Inc. and is looking into claims regarding possible securities fraud or other unlawful practices by the company and its officers [1]. - The investigation was prompted by a report from Hunterbrook Media, which alleged that DexCom made unauthorized design changes to a critical component of its G7 glucose monitoring system, leading to serious health consequences for users [2]. Group 2: Market Reaction - Following the release of the Hunterbrook report, DexCom's stock price experienced a significant decline, falling by $8.99 per share, or 11.76%, closing at $67.45 per share on September 19, 2025 [2].